This site uses cookies to enhance your browsing experience. By continuing navigation, you agree to the use of cookies. For more information about our use of cookies, see our Privacy Policy.

Paul LaViolette

April 11, 2017 |

Mr. LaViolette is Managing Partner at SV Health Investors, a leading life sciences growth equity and venture capital investor.   He leads medical device investing at SVHI and is currently investing the Medtech Convergence Fund.  He is presently chairman of the board for:  CardioFocus, Corvia Medical, Endotronix, Misonix, Inc., Stimwave and TransEnterix.  He also serves as lead director for Bardy Diagnostics and director for Clarify Medical and CSA Medical. In addition, Mr. LaViolette is a director for Edwards Lifesciences, the recent past chairman and current director of MDMA, the medical device industry association, and Chairman of the Innovation Growth Board Mass General Brigham.

Prior to joining SV Health Investors, Mr. LaViolette spent nearly three decades building and leading medical device businesses.   Most recently, he spent 15 years at Boston Scientific Corporation where he served at various times as President of Cardiology, President of International, Group President of Cardiovascular, Group President of Endosurgery and Chief Operating Officer. During Mr. LaViolette’s tenure, Boston Scientific grew 25-fold.  Prior to joining BSC, Mr. LaViolette spent 14 years at CR Bard and Kendall Corporation in general management and commercial leadership roles.

Mr. LaViolette received his BA in Psychology from Fairfield University (1979) and his MBA from Boston College (1981).

Top